Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01853345 · ClinicalTrials.gov registry record

iCAT for Recurrent/Refractory/HR Solid Tumors

A clinical trial of Sarcoma and Neuroblastoma, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
101
Enrollment target
5
Study locations

NCT01853345 is a study of Sarcoma and Neuroblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 101 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01853345, a study of Sarcoma and Neuroblastoma, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
101 participants
Enrollment target
5
Study locations

Study Summary

In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling results and determine whether there is a cancer-causing alteration present in the tumor. If there is, the experts will determine if there is a targeted drug available that could counteract this alteration. If there is an alteration identified and a targeted drug available the panel of experts will make an individualized treatment recommendation. The results of the tumor profiling and the individualized treatment recommendation can be shared with the primary oncologist.

Conditions Studied

Sarcoma Neuroblastoma Wilms Tumor Pediatric Solid Tumor

Study Locations (5)

Massachusetts

  • Dana-Farber Cancer Institute - Boston
  • Boston Children's Hospital - Boston

California

  • University of California, San Francisco - San Francisco

District of Columbia

  • Children's National Medical center - Washington D.C.

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2012-08

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01853345

The ClinicalTrials.gov registry entry for NCT01853345 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Sarcoma appearing as the primary indexed condition, and to 0 interventions.

NCT01853345 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01853345 about?

NCT01853345 is a clinical study titled "iCAT for Recurrent/Refractory/HR Solid Tumors". In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling results and determine whether there is a cancer-causing alteration present in the tumor. If there is...

What is the current status of trial NCT01853345?

This trial is currently completed. The enrollment target is 101 participants. The study started on 2012-08.

What conditions does trial NCT01853345 study?

This clinical trial studies the following conditions: Sarcoma, Neuroblastoma, Wilms Tumor, Pediatric Solid Tumor.

Who is sponsoring clinical trial NCT01853345?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01853345 being conducted?

This trial has 5 study locations across California, District of Columbia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Neuroblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.